TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented history of moderately-severe to severe hemophilia B (FIX activity \</=2%).~* Male subjects, aged 12 years to 65 years.~* Subjects with at least 100 exposure days (EDs) to factor IX products.~* Subjects with a minimum of 12 bleeding episodes, 6 of which must be joint bleeds, in the 12-month period before the Screening visit.~Exclusion Criteria:~* Subjects who have received FIX as a primary or secondary prophylaxis regimen within the last 12 months prior to the Screening visit.~* Subjects who have had major surgery or an orthopedic surgical procedure within the past 3 months prior to Screening visit.~* Subjects for which major surgery or orthopedic surgery is planned within the duration of study participation.~* Subjects with a past history of, or current FIX inhibitor, defined as \>ULN (upper limit of normal) of the reporting laboratory.~* Subjects with a known hypersensitivity to any FIX product or hamster protein.

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BeneFIX (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have completed six months of maintenance treatment in the SP513 double-blind trial~Exclusion Criteria:~* Subjects who had an ongoing serious adverse event from SP513 double-blind trial that was assessed as related to study medication

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rotigotine (Type: EXPERIMENTAL): Rotigotine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment With Erythropoietin and Cognition During Hypoglycaemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes~* Hypoglycaemia unawareness~* 2 or more episodes of hypoglycaemia in the last 12 months~* Age \>18 år~* Duration of diabetes \> 5 år~* Weight \> 50 kg~* No pregnancy~* Informed consent~Exclusion Criteria:~* Pregnancy~* Heart failure (NYHA 2-4)~* Ischaemic heart disease~* Epilepsy~* Venous thromboembolic disease~* Thrombocytosis~* Beta receptor antagonists~* Disturbance of vision~* History of stroke~* History of erythropoietin treatment~* Plasma-creatinin \> 100 umol/l (male)or 88 umol/l (female)~* Plasma-haemoglobin \< 7,0 or \> 11 mmol/l at time of inclusion~* Operation with blood loss within the last 6 weeks~* Cancer~* Treated with ciclosporin~* Suspicion of non-compliance with protocol~* Conditions incompatible with participation - e.g. safety considerations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Isotonic NaCl, intravenously injection
- Active (Type: EXPERIMENTAL): Epoetin alfa, injected

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Diagnostic Yield of an Ambulatory Patch Monitor in Unexplained Emergency Department Syncope: A Pilot Study (PATCH-ED)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 16 years or over presenting within 6 hours of an episode of syncope and whose syncope remains unexplained after ED assessment. Syncope will be defined as a transient loss of consciousness (TLOC) with inability to maintain postural tone and immediate complete spontaneous recovery without medical intervention (to preexisting mental status and neurologic function)~Exclusion Criteria:~* Obvious underlying cause after ED assessment,~* Alcohol or illicit drugs as presumptive cause of TLOC \[24\],~* Epileptic seizure as presumptive cause of TLOC (seizure activity with a \>15 min witness reported post-ictal phase) \[24\],~* Stroke ⁄ transient ischemic attack as presumptive cause of TLOC \[24\],~* Head trauma followed by TLOC \[24\],~* Hypoglycemia as presumptive cause of TLOC \[24\],~* No consent i.e. patient lacking capacity,~* Previous recruitment into the study,~* Patient in custody or prison.~Obvious underlying causes will be defined as:~* Clinical history of vasovagal syncope i.e. pre-syncope symptoms and low-risk patient according to current ESC guidelines \[14\],~* Arrhythmia on ED ECG thought to have caused syncope,~* Arrhythmia on pre-hospital ECG causing syncope,~* Pulmonary embolism (PE) diagnosed on Computed Tomography Pulmonary Angiography (CTPA; or equivalent e.g. symptoms of PE plus positive leg ultrasound scan/ventilation-perfusion scan/echo),~* Postural hypotension (postural drop \>20 mmHg in ED with symptoms during test and suggestive history),~* Myocardial Infarction \[25\],~* CT brain or clinical signs/symptoms in ED showing cerebrovascular accident or subarachnoid haemorrhage,~* Evidence of haemorrhage in ED thought to have caused syncope,~* Other obvious cause of syncope apparent in ED.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single study arm (Type: EXPERIMENTAL): All enrolled patients will be fitted with a novel ambulatory patch (ZIO®Patch), which continuously records heartbeats for up to 14 days. Brain natriuretic peptide (BNP) and hs-troponin I at 0 and 3 hours post ED attendance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D in Ventilated ICU Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Receiving care in an intensive care unit (ICU)~* Age greater than 18 years~* Expected to require mechanical ventilation for at least 72 hours after entry~* Expected to survive and remain in the ICU for at least 96 hours after study entry~* To enable delivery of study drug, the subject has enteral access in place and is deemed able to tolerate enteral drug administration~Exclusion Criteria:~* Inability to obtain or declined informed consent from the subject and/or legally authorized representative~* Pregnancy~* Ongoing shock~* Current hypercalcemia (albumin-corrected serum calcium \> 10.8 mg/dL or ionized calcium \> 5.2 mg/dL)~* History of therapy with high-dose vitamin D to treat vitamin D deficiency within previous 6 months~* History of disorders associated with hypercalcemia; history of cancer with history of hypercalcemia within the past 1 year, hyperparathyroidism, sarcoidosis, nephrolithiasis\]~* Chronic renal dysfunction requiring chronic dialysis~* Known history of cirrhosis~* History of AIDS~* The patient has received any investigational drug within 60 days prior to study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enteral vitamin D3 50,000 IU (Type: EXPERIMENTAL): An arm where subjects receive 50,000 IU of Vitamin D for 5 days.
- Enteral Vitamin D3 100,000 IU (Type: EXPERIMENTAL): Arm where subjects receive 100,000 IU of Vitamin D for 5 days
- Inactive Substance (Type: PLACEBO_COMPARATOR): Arm where patients receive inactive substance for 5 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Participants who are diagnosed as Lennox-Gastaut syndrome with tonic/atonic seizures and atypical absence seizures (A history of atypical absence seizures will also be incorporated).~2. Participants who had a slow spike-and-wave pattern in an electroencephalogram within 6 months prior to the enrollment for the Observation Period.~3. Participants who had at least a total of 90 seizures in the 28 days prior to the enrollment for the Observation Period.~4. Participants who have been on 1 - 3 anti-epileptic drugs from 28 days prior to the enrollment for the Observation Period and have not changed the type of the anti-epileptic drugs.~5. Participants who have not changed the type nor the dose or administration of the anti-epileptic drugs they are taking in the Observation Period.~Exclusion criteria;~1. Participants who had a history of generalized tonic-clonic status epilepticus within baseline.~2. Participants who received drug therapy at least 4 times to be rescued from status epilepticus within baseline.~3. Participants who had a history of hypoxia which needed emergency resuscitation within 12 months prior to the Treatment Period.~4. Participants who were on a ketogenic diet or have received adrenocorticotropic hormone (ACTH) therapy or Vitamin B6 therapy within 6 months prior to the Treatment Period.~5. Participants who had a history of suicide attempt within the 1 year prior to the Treatment Period.~6. Participants who had a history of or has an allergy to triazole compound.~7. Participants who have clinically significant electrocardiogram abnormalities at baseline.~8. Participants who are pregnant, who may be pregnant, who are lactating or who wish to be pregnant.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Rufinamide (E2080) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Renal Safety of Tenofovir Alafenamide in HBV-related Acute-on-chronic Liver Failure: Real-World Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* the presence of hepatitis B surface antigen (HBsAg) in the serum for at least 6 months.~* evidence of active viral replication as documented by measurable HBV DNA in the serum (≥2000IU/mL).~Exclusion Criteria:~* Less than 18 years old.~* history of ESKD or kidney transplantation.~* unknown baseline estimated glomerular filtration rate (eGFR).~* coexistence with other liver diseases such as alcoholic liver disease, autoimmune hepatitis, drug-induced liver injury, or other viral infections(hepatitis A, C, and E virus or HIV infection).~* concomitant with malignant tumor or other serious diseases affecting survival time.~* patients with missing data. follow-up period of \<48 weeks.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tenofovir alafenamide (Type: EXPERIMENTAL): tenofovir alafenamide,Gilead Sciences,capsule,25 mg,once a day,Continuous use for 48 weeks.
- entecavir (Type: EXPERIMENTAL): entecavir,Fujian cosunter pharmaceutical co.LTD,capsule,0.5mg,once a day,Continuous use for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of Umbilical Cord Mesenchymal Stem Cells Combined With Collagen Scaffold in the Treatment of Thin Endometrium

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. According to the GCP regulations, obtain the informed consent of the subject, volunteer for the test, and have signed the informed consent form.~2. Women aged 20-40 years with fertility requirements~3. Infertility patients who are treated in this hospital~4. After more than 2 times of hysteroscopic adhesion separation surgery, the uterine cavity morphology has basically returned to normal. The patient has a normal menstrual cycle or an estrogenic dose of 6 mg per day, and the highest thickness of the endometrium is 5.5 mm in 6 cycles by ultrasound.~5. or receive adjuvant reproductive treatment, the endometrial thickness is less than 5.5mm for unknown reasons, the treatment of estrogen, colony stimulating factor, aspirin, sildenafil and other drugs up to 8mg / day is invalid.~6. HBVAg negative, HCV negative, HIV negative, syphilis negative~7. Normal bone marrow morphology, normal blood routine~8. Previously failed to receive relevant stem cell therapy~Exclusion Criteria:~1. Those who cannot accept the treatment observation process required by the test~2. There are contraindications for hysteroscopic surgery;~3. congenital uterine malformation; severe adenomyosis; uterine fibroids that may affect embryo implantation; the investigators judged that there are other uterine factors that are not suitable for embryo implantation~4. Patients with chromosomal abnormalities~5. contraindications to estrogen therapy; systemic diseases such as thrombosis, cardiopulmonary disease, hematopoietic diseases, malignant tumors, etc.~6. Patients without fertility requirements

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- stem cell therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of SPD503 in Combination With Psychostimulants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects with ADHD currently taking a stable dose of psychostimulant for at least 4 weeks~* Aged 6-17 years with a sub-optimal~* Partial response to stimulants~* Subjects must be \< 95th percentile for BMI with weight \>= 55lbs and \<= 176lbs

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- SPD503-AM (Type: EXPERIMENTAL): SPD503 (Guanfacine Extended Release)
- SPD503-PM (Type: EXPERIMENTAL): SPD503 (Guanfacine Extended Release)
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages between 18-40 years~* Males \& females~* patients between the ages of 18 and 53 who met the diagnostic criteria for schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (20), with a minimum disease duration of two years.~* stable on risperidone for a minimum of 8 weeks~* clinically stable for at least 4 weeks prior to study.~* willing to give informed consent.~* able to take medication orally.~Exclusion Criteria:~* Acute, unstable, significant or untreated medical illness beside schizophrenia;~* Pregnant or breast-feeding females;~* History of substance abuse or dependence in the past 3 months.~* Known contraindication to pentoxifylline treatment.~* Any serious or life-threatening medical conditions or neurological problem, severe extrapyramidal symptoms, history of abnormal bleeding, presence of hypothyroidism, renal disease, cardiovascular problems, rising liver transaminases to 3 times the upper limit of normal or higher

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): Equivalent Placebo will be given
- Pentoxifylline group (Type: EXPERIMENTAL): Pentoxifylline will be given orally at 800 mg a day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Dexmedetomidine and Haloperidol in Patients With Intensive Care Unit (ICU)-Associated Agitation and Delirium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients will be eligible for the study if, in the opinion of the treating clinician, they continue to require mechanical ventilation only because their degree of agitation requires such a high dose of sedative medication (midazolam or propofol, the only commonly used specific sedatives in our unit) that extubation is not possible.~Exclusion Criteria:~* Patients who could not be extubated even if delirium or agitation were corrected. This will include:~  * Patients receiving high dose opioid analgesia (\>20 m/morphine/day)~ * Patients shortly to return to the operating theatre~ * Patients undergoing repeated invasive procedures, in whom it is desirable to maintain deep sedation.~ * Patients likely to require ongoing airway protection or control, or ventilatory support (for example, spinal patients with an inadequate vital capacity)~* Known allergy to haloperidol or alpha2 agonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Recovery Following Opioids Free Anaesthesia in Laparoscopic Sleeve Gastrectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 70 ASA II - III adult patients (18-60 years old)~* Elective laparoscopic bariatric surgery.~* Body mass index (BMI) is from 40 to 60~* Trocar sites at or above the umbilicus (T 10 dermatome).~Exclusion Criteria:~* Allergy to amino-amide local anaesthetics,~* presence of coagulopathy~* local skin infection at injection sites,~* preoperative chronic dependence upon opioid and NSAID medications,~* liver or renal insufficiency,~* history of psychiatric or neurological disease, deafness,~* previous open surgery,~* patients who need to be converted to open surgery with more tissue trauma,~* ASA (American society of anesthesiologists) class above III were excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Opioids anesthesia (Type: ACTIVE_COMPARATOR): received propofol-fentanyl induction of anaesthesia plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side
- OFA (Type: ACTIVE_COMPARATOR): received preinduction with dexmeditomidine 0.1µg.kg-1 over 10 min. Induction with propofol 1.5 mg.kg-1-ketamine (ketofol 3:1 mixture) induction plus maintenance mixture of dexmedetomidine 0.5µg.kg-1.h-1, ketamine 0.5mg.kg-1.h-1, and lidocaine 1 mg.kg-1.h-1 plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ISSUE3: International Study on Syncope of Uncertain Etiology 3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suspected or certain neurally-mediated syncope, based on the Guidelines recently published by the Task Force on Syncope of the European Society of Cardiology 2,3 (Appendix 1);~* More than 3 syncope episodes in the last 2 years;~* Clinical presentation of syncope of sufficient severity requiring treatment initiation in the physician's and patient's judgement.~* Age \> 40 years.~* Negative carotid sinus massage.~* Patients accept to have an ILR implantation.~Exclusion criteria:~* Carotid sinus hypersensitivity~* Suspected or certain heart disease and high likelihood of cardiac syncope:~* Symptomatic orthostatic hypotension diagnosed by standing blood pressure measurement;~* Loss of consciousness different from syncope (e.g. epilepsy, psychiatric, metabolic, drop-attack, TIA, intoxication, cataplexy);~* Subclavian steal syndrome;~* Psychologically or physically (due to any other illness) or cognitively unfit for participation in the study according to the opinion of the investigator;~* Patient compliance doubtful;~* Patient geographically or otherwise inaccessible for follow-up;~* Patient unwilling or unable to give informed consent;~* Life expectancy \<1 year.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dual chamber pacemaker (Type: PLACEBO_COMPARATOR): Dual chamber pacemaker programmed ODO (switched OFF)
- Dual chamber pacemeker (Type: ACTIVE_COMPARATOR): Medtronic dual chamber pacemaker programmed ON and with Rate Drope Response programmed ON

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete